{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9"},{"groupId":"OG001","value":"89.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"TC1/2/3 or IC1/2/3 subgroup of PP","reportingStatus":"POSTED","timeFrame":"Baseline up to PD or Death (up to approximately 2.25 years)","title":"Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}